EcoDrugPlus

Toll Like Receptor 7

Ensembl ID : ENSSHAG00000020704
Gene Symbol: TLR7
4 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 8

Ensembl ID : ENSSHAG00000013998
Gene Symbol: TLR8
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Trace Amine Associated Receptor 1

Ensembl ID : ENSSHAG00000025054
Gene Symbol: TAAR1
4 Cross references
602 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSSHAG00000016699
Gene Symbol: TGFBR1
4 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha 1a

Ensembl ID : ENSSHAG00000025605
Gene Symbol: TUBA1A
4 Cross references
86 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Alpha-3 Chain

Ensembl ID : ENSSHAG00000023105
Gene Symbol: LOC116420883
3 Cross references
175 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 1 Class Vi

Ensembl ID : ENSSHAG00000013053
Gene Symbol: TUBB1
4 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 2a Class Iia

Ensembl ID : ENSSHAG00000021520
Gene Symbol: TUBB2A
4 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 2b Class Iib

Ensembl ID : ENSSHAG00000007892
Gene Symbol: TUBB2B
4 Cross references
181 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 3 Class Iii

Ensembl ID : ENSSHAG00000007149
Gene Symbol: TUBB3
4 Cross references
144 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta 6 Class V

Ensembl ID : ENSSHAG00000006931
Gene Symbol: TUBB6
4 Cross references
141 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Tubulin Beta Class I

Ensembl ID : ENSSHAG00000028751
Gene Symbol: TUBB
4 Cross references
358 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).